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How to interpret figures in reports of clinical trials
A picture may be worth a thousand words but in medical research, caution Stuart Pocock, 
Thomas Travison, and Lisa Wruck, it is important to understand exactly what you are looking at
The graphical display of data is among the most power-
ful tools available for communicating medical research 
findings, given the increasing complexity of study 
designs and the mind’s preference for information con-
veyed in pictorial format.1 2 However, although general 
information is available on what constitutes an effective 
data display1 -6 and what constitutes good practice in 
reporting trials,7 8 there is relatively little guidance on 
using figures to aid the presentation of trial results.9
Because figures are so effective in creating an endur-
ing impression of results, their construction—and inter-
pretation by readers—must be handled with care. We 
recently conducted a survey to determine the types of 
figures used most commonly in reports of clinical trials 
and to uncover the good, and not so good, practices 
that typically attend their use.10 Here, we highlight 
the important features of the most commonly used 
types of figures. In doing so, we hope to illustrate 
the hallmarks of figures that are likely to convey an 
impression consistent with valid trial conclusions and 
those aspects of figures that may, without careful inter-
pretation, be misleading.
What comes up most
We examined all issues of five major general medical 
journals (Annals of Internal Medicine, BMJ, JAMA, Lancet, 
and New England Journal of Medicine) published from 
November 2006 to January 2007. The 77 reports of ran-
domised trials included in these journal issues contained 
175 figures (mean 2.3 figures per article). The four most 
common types of figure were flow diagrams (66 articles), 
Kaplan-Meier plots (32 articles), forest plots (21 articles), 
and repeated measures plots (20 articles) (see table on 
bmj.com).10 
Flow diagrams 
Flow diagrams are integral to the CONSORT guide-
lines for the reporting of clinical trials.7 8 They display 
the flow of participants through the stages of the trial in 
a way that should be easy to follow. Figure 1 depicts a 
successful example of a flow diagram portraying a clear 
picture of the trial’s design and conduct. It includes the 
numbers of people screened and reasons for exclusion, 
information that many trials fail to collect and report. 
The numbers not receiving randomised treatment and 
numbers lost to follow-up are key limitations that every 
study should document.
The flow chart in fig 2 is harder to read because it con-
tains substantial repetition of words. Such flow diagrams 
in multi-arm trials may be more concisely displayed as a 
table, provided there is no loss of information.
Kaplan-Meier plots 
The Kaplan-Meier plot is for time to event or survival 
data, when interest is focused on the risk of a particu-
lar event (such as death or myocardial infarction) as 
participants move through time.13 Because the aim of 
many treatments or interventions is to try to reduce the 
occurrence of a particular event, this type of plot is used 
commonly in reporting clinical trials. However, it is an 
aspect of statistics not well understood by doctors.14
The plot is drawn with time in the study on the 
horizontal axis and either the cumulative proportion 
with the event, or the proportion for whom the event 
has not yet occurred (the survival probability), plotted 
on the vertical. Curves are drawn for each treatment 
group, and the separation between the curves indi-
cates potential differences in the treatments’ effective-
ness. The Kaplan-Meier estimates change only when 
events actually occur, so that each plot is a series of 
steps. Note how few participants were followed to five 
years.
Figure 3 shows the essential features of a clear 
Kaplan Meier plot. The treatment groups are visu-
ally differentiable, with an appropriate vertical scale 
and axes clearly labelled. Below the horizontal axis, 
the numbers of participants remaining at risk (that is, 
those who remain under observation and for whom 
the event is yet to occur) are displayed. 
A formal statistical comparison (in this case a hazard 
ratio with 95% confidence interval and P value from the 
logrank test) is needed to assess whether the distance 
between the curves is sufficient to depict a real differ-
ence in risk between treatment and control arms. This 
information is often best included on the figure itself. In 
this case the slight difference is not significant.
Figure 4 shows a plot going down (plotting the pro-
portion of participants who are event free), covering 
389 Excluded
  74 Did not meet inclusion criteria
  192 Declined participation
  123 Had other reasons
546 Patients screened
157 Underwent randomisation
51 Assigned to surgical group
  48 Underwent surgery
  3 Did not undergo surgery
    1 Underwent embolisation
    2 Were not treated
6 Were lost to follow-up
45 Included in analysis95 Included in analysis
11 Were lost to follow-up
106 Assigned to embolisation group
  101 Underwent embolisation (including 3
    technical failures)
  5 Did not undergo embolisation
Fig 1 | Flow diagram from study comparing uterine-artery embolisation with surgery for fibroids 
(redrawn from Edwards et al11)
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the whole scale from probability 1 to 0. Much of the 
graph is empty space because the event (defaulting 
from treatment) has low incidence. For outcomes of 
this type, it is more useful to present the cumulative 
probability curve going up, with the vertical axis trun-
cated at a reasonable maximum.
It can be helpful if Kaplan-Meier plots take account 
of statistical uncertainty by displaying standard error 
bars (or confidence intervals) at a few key follow-up 
times13 to help restrain readers from overinterpreting 
any apparent differences between the curves. 
Forest plots 
A forest plot displays estimated treatment effects 
across various patient subgroups.17 Typically, a forest 
plot presents an overall effect (for all randomised par-
ticipants) and then various subgroup computations (for 
instance, by sex) on a common axis. Each point plotted 
represents a comparison between treatment and control 
participants in the relevant subgroup and is accompa-
nied by its 95% CI.
Figure 5 is a simple example of a forest plot, with only 
one set of subgroup analyses.18 This figure has several 
features consistent with good practice. It shows the over-
all estimate and confidence intervals (combining all sub-
groups) and the labels indicate which direction favours 
treatment or control. Subgroup estimates are displayed 
underneath the overall estimate. Although the lines sug-
gest that patients with a baseline albumin concentra-
tion below 25 g/l may benefit from albumin treatment, 
inclusion of  the heterogeneity test (sometimes called 
interaction test) makes it clear that the evidence is not 
strong enough to be conclusive. Such interaction tests 
are key to interpretation of forest plots19 20 and should 
be included on the plot or in the legend.
When forest plots display ratios (as in fig 5) rather 
than absolute differences, the horizontal axis may be 
on a logarithmic scale, so that a ratio of 2 is depicted 
as being as far away from 1 as is 0.5. This makes sense 
because 2 is the multiplicative inverse of 1/2.
Extra numerical information is often tabulated 
alongside the figure. In fig 5 the numbers of deaths 
and patients (to the left of the plotted estimates) are 
helpful as they are the “raw data” for each subgroup.
Most forest plots present several subgroup analyses 
(fig 6). Presentation of results in both tabular and graph-
ical format allows readers to examine the effects with 
precision and facilitates inclusion of data in subsequent 
meta-analyses. However, fig 6 does not give the results 
of heterogeneity tests; instead the authors state “there 
was no evidence of substantial heterogeneity.” 
This figure displays some additional conventions 
consistent with good practice. Vertical lines are plotted 
both for the value indicating no treatment effect (dotted 
at 1.0) and for the overall effect (solid, at 0.64). In addi-
tion, the size of the plotted symbol for point estimates 
is proportional to the number of events within each 
subgroup. Forest plots are also used in meta-analyses 
Randomised (n=325)
Retrospective record review (n=439)
Allocated to control
intervention (n=108)
Direct referrals from GPs (n=252)
Protocol violation (n=1)
Allocated to enhanced
pharmacy review (n=108)
Protocol violation (n=1)
Did not receive allocated
  intervention (n=2)
Allocated to community
physiotherapy (n=109)
Received allocated
intervention (n=107)
Lost to follow-up (n=19)
Returned questionnaires (n=92)
Pain/function scores (n=89/90)
Received allocated
intervention (n=105)
Received allocated
intervention (n=99)
Protocol violation (n=0)
Did not receive allocated
  intervention (n=10)
Follow-up and
analysis at 3 months
Lost to follow-up (n=15)
Returned questionnaires (n=98)
Pain/function scores (n=93/94)
Follow-up and
analysis at 6 months
Lost to follow-up (n=21)
Returned questionnaires (n=90)
Pain/function scores (n=87/89)
Lost to follow-up (n=9)
Returned questionnaires (n=100)
Pain/function scores (n=98/96)
Lost to follow-up (n=7)
Returned questionnaires (n=103)
Pain/function scores (n=100/94)
Lost to follow-up (n=13)
Returned questionnaires (n=99)
Pain/function scores (n=94/92)
Lost to follow-up (n=16)
Returned questionnaires (n=97)
Pain/function scores (n=93/95)
Lost to follow-up (n=18)
Returned questionnaires (n=96)
Pain/function scores (n=91/94)
Lost to follow-up (n=19)
Returned questionnaires (n=97)
Pain/function scores (n=90/93)
Follow-up and
analysis at 12 months
Excluded (n=315):
  No response to invitation letter (n=283)
  Refused to participate (n=15)
  Did not meet inclusion criteria (n=17):
    No current knee pain (n=7)
    Recent injection/physiotherapy (n=6)
    Waiting for TKR (n=2)
    Does not read English (n=2)
Excluded (n=51):
  Refused to participate (n=38)
  Did not meet inclusion criteria (n=13):
    Aged under 55 years (n=6)
    Recent injection/physiotherapy (n=3)
    No current knee pain (n=2)
    No telephone (n=1)
    Does not read English (n=1)
Fig 2 | Flow diagram for randomised trial of three primary care strategies for knee pain12
Fig 3 | Kaplan-Meier curve from trial of percutaneous coronary 
intervention (PCI) for persistent occlusion after myocardial 
infarction. The primary end point was death from any cause, 
non-fatal reinfarction, or heart failure requiring hospital 
admission (Redrawn from Hochman et al15)
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Fig 4 | Kaplan-Meier plot from trial of strategies to improve 
adherence to tuberculosis treatment (redrawn from Thiam 
et al16)
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combining evidence from several related studies, where 
the same issues arise.
Repeated measures plots 
For trials with a quantitative outcome measured at base-
line and two or more follow-up times, it is common to 
plot the means by treatment over time. Figure 7 shows 
this approach in a clear style for three outcome scores 
each recorded at baseline and five follow-up times. The 
figure uses different symbols for each treatment to help 
distinguish them, and joining the means by lines helps 
the eye to follow the trends over time.
As with the forest plots, it is important to express the 
statistical uncertainty in each mean; this is done here 
using confidence intervals. To enhance clarity, the 
authors have helpfully staggered group means at each 
time to ensure that intervals do not obscure each other. 
The figure also includes a global P value correspond-
ing to a test of overall differences in outcomes between 
study arms. This avoids the undesirable use of repeated 
significance tests at every time point and the consequent 
problem of inflated type I error due to multiple testing.
As a longitudinal study will typically lose some 
 participants with time, it would have been useful to give 
the numbers of participants at each time point under the 
x axis, as in fig 3. 
Figure 8 uses a different approach to displaying 
 longitudinal trends, plotting mean changes from baseline 
rather than means. Analyses of covariance adjusting for 
baseline value is a preferred method of inference for such 
data.23 The numbers of patients by group at each time 
are given below the x axis. The authors documented 
the statistical comparison of treatments at final visit, an 
important detail that clarifies that the observed treatment 
differences remained significant. However, their use of 
Subgroup (No of patients)
Region of the world
  Europe, Canada, South Africa, Australia, New Zealand (2438)
  Asia Pacific, Japan (405)
  Eastern Europe (369)
  Central and South America (189)
Age at randomisation
  <35 years (253)
  35-49 years (1508)
  50-59 years (1096)
  ≥60 years (544)
Menopausal status at randomisation
  Premenopausal (491)
  Uncertain (1373)
  Postmenopausal (1535)
Nodal status
  Not assessed (neoadjuvant chemotherapy (372)
  Negative (1099)
  1-3 positive nodes (976)
  ≥4 positive nodes (953)
Pathological tumour size
  Any (neoadjuvant chemotherapy (372)
  0-2 cm (1351)
  >2-5 cm (1482)
  >5 cm (171)
Hormone receptor status
  ER-negative x PgR-negative (1627)
  ER-negative x PgR-positive (172)
  ER-positive x PgR-negative (460)
  ER-positive x PgR-positive (984)
Histological grade
  3 - poorly differentiated (2047)
  2 - moderately differentiated (1111)
Surgery for primary tumour
  Breast-conserving procedure (1432)
  Mastectomy (1968)
Previous radiotherapy
  Yes (2606)
  No (795)
Type of (neo)adjuvant chemotherapy
  No anthracyclines (202)
  Anthracyclines, no taxanes (2310)
  Anthracyclines and taxanes (889)
All patients (3401)
No of events
trastuzumab
v observation
161 v 235
21 v 37
23 v 36
13 v 13
19 v 31
89 v 150
71 v 97
39 v 43
43 v 49
70 v 135
105 v 137
39 v 50
34 v 58
50 v 80
95 v 132
39 v 50
61 v 95
97 v 150
20 v 25
126 v 190
12 v 12
26 v 39
46 v 61
157 v 201
47 v 97
77 v 121
141 v 200
183 v 265
35 v 56
12 v 15
132 v 221
74 v 85
218 v 321
0.66 (0.54 to 0.81)
0.53 (0.31 to 0.90)
0.54 (0.32 to 0.91)
0.98 (0.45 to 2.11)
0.57 (0.32 to 1.01)
0.54 (0.42 to 0.70)
0.71 (0.52 to 0.97)
0.91 (0.59 to 1.41)
0.80 (0.53 to 1.21)
0.48 (0.36 to 0.64)
0.75 (0.58 to 0.97)
0.66 (0.43 to 1.00)
0.59 (0.39 to 0.91)
0.61 (0.43 to 0.87)
0.64 (0.49 to 0.83)
0.66 (0.43 to 1.00)
0.65 (0.47 to 0.90)
0.55 (0.43 to 0.71)
1.14 (0.63 to 2.06)
0.63 (0.50 to 0.78)
0.77 (0.34 to 1.74)
0.82 (0.50 to 1.34)
0.63 (0.43 to 0.93)
0.73 (0.59 to 0.90)
0.46 (0.33 to 0.65)
0.59 (0.44 to 0.79)
0.68 (0.55 to 0.84)
0.64 (0.53 to 0.77)
0.64 (0.42 to 0.98)
0.76 (0.35 to 1.62)
0.57 (0.46 to 0.71)
0.80 (0.59 to 1.10)
0.64 (0.54 to 0.76)
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
0 0.5 1.0 1.5
Fig 6 | Forest plot from trial of adjuvant chemotherapy in HER2-positive breast cancer showing 
hazard ratio for disease free survival (redrawn from Smith et al21)
Fig 7 | Means scores over time for SF-36 bodily pain and 
physical function scales and Oswestry disability index from a 
study of surgical versus non-operative treatment for lumbar 
disc herniation (redrawn from Weinstein et al22)
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Fig 5 | Forest plot from study comparing resuscitation with albumin or saline in intensive care 
showing unadjusted odds ratio of death stratified by baseline albumin concentration18
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ing results, the visual impression of a clinically relevant 
treatment effect needs clarifying by formal statistical evi-
dence. We hope that the above advice will help readers 
to spot any deficiencies in figures and make their own 
wise interpretation of trial results. 
All figures are reproduced with permission from the original journals.
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last observation carried forward is less desirable than an 
appropriate repeated measures model. Some trial reports 
may plot medians or percentages in certain categories 
rather than means over time, especially if the data are 
skew or categorical in nature.
Assessing visual evidence for a treatment difference
When a figure compares two treatments it is useful 
for readers to infer how the (lack of) overlap between 
standard errors or between confidence intervals indi-
cates the strength of evidence for a treatment difference. 
The limits of a 95% confidence interval are about twice 
the standard error, slightly more if samples are small 
for a quantitative outcome. The following rough guide 
works well when two treatment groups have similar 
standard errors, which is often the case. Any overlap 
between the standard error bars means the difference 
is not significant. If there is a gap between the stand-
ard error bars that exceeds one standard error then 
the difference is significant, at P<0.035 in fact. Thus, a 
smaller gap may fall short of conventional significance. 
No overlap between 95% confidence intervals indicates 
strong evidence of a difference (P<0.006). So, a slight 
overlap between two 95% confidence intervals may 
still be significant.
It is important to note whether error bars are stand-
ard errors or confidence intervals, and to remember 
that displays of individual variability (such as standard 
deviations or interquartile ranges) do not help directly 
in detecting treatment differences.
Although figures are an important aid to interpret-
SummArY PoINTS
Clinical trials contain four 
main types of figure: flow 
diagrams, Kaplan-Meier 
plots, forest plots, and 
repeated measures plots
Many published figures 
have deficiencies in 
presentation or content
Examples highlight good 
practice and pitfalls to 
avoid when interpreting 
figures
What makes a good figure?
In our survey, figures were 
rarely explicitly misleading 
but some improvements 
could do much to enhance 
clarity. To this end all 
figures should:
Emphasise clarity and be •	
oriented to their primary 
goal
Be independently •	
interpretable
Display measures of •	
uncertainty when any 
estimates are plotted.
Fig 8 | Changes in carotid intima-media thickness (CIMT) over 
time (redrawn from Mazzone et al24). Values are least square 
means using last observation carried forward and error bars 
are standard errors
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